Cargando…
COVID-IP: staring down the Bayh–Dole Act with 2020 vision
As the human and economic toll of the COVID-19 coronavirus steadily escalates, there is extreme uncertainty regarding the timeframe for prevention, detection, and treatment. There is also concern about the eventual costs associated with approved products and the barriers to access created by the pat...
Autor principal: | Paradise, Jordan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532545/ https://www.ncbi.nlm.nih.gov/pubmed/33033619 http://dx.doi.org/10.1093/jlb/lsaa073 |
Ejemplares similares
-
The Stakes in Bayh-Dole: Public Values Beyond the Pace of Innovation
por: Valdivia, Walter D.
Publicado: (2011) -
Is Bayh-Dole Good for Developing Countries? Lessons from the US Experience
por: So, Anthony D, et al.
Publicado: (2008) -
NIH funding for patents that contribute to market exclusivity of drugs approved 2010–2019 and the public interest protections of Bayh-Dole
por: Ledley, Fred D., et al.
Publicado: (2023) -
Staring down the barrel of COVID-19
por: Suryawanshi, Milind Prasannakumar, et al.
Publicado: (2020) -
A Doleful Picture
Publicado: (1888)